In mid-May 2021, the Dutch Healthcare Institute (ZIN) published an advice "Molecular Diagnostics: determining the position on molecular diagnostics in oncology," which was developed at the request of the Ministry of Health, Welfare and Sport.
The objective of the position is to organize molecular diagnostics within standard regular care and develop a framework for the accessibility and integral implementation of new tests in practice. To achieve appropriate use of molecular diagnostics in oncology. It is necessary to make agreements on the organization and funding of this care with all involved parties. The framework, therefore, includes the following elements:
- Effectiveness and location;
- Organization of care;
- Data infrastructure;
The ZIN divided the advice into two parts. Part number one is the advice in the form of an action plan that describes the steps required. In part number two, the ZIN will work out these steps together with the involved parties.
Furthermore, on May 19, 2021, in the Letter to Dutch Parliament, the Minister of Health, Welfare and Sport asked the ZIN to take the lead in implementing the advice in collaboration with all parties involved, including monitoring of work on mutual agreements between involved parties and development of a quality standard. The timetable for implementation of the Action Plan has not been defined yet.
The full details in Dutch can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).